Trade Compugen Ltd. - Ordinary Shares - CGEN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0396 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001207% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.3752 |
| Open | 1.4052 |
| 1-Year Change | -25.94% |
| Day's Range | 1.3752 - 1.4452 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2025 | 1.4252 | 0.0300 | 2.15% | 1.3952 | 1.4452 | 1.3652 |
| Apr 21, 2025 | 1.3752 | 0.0000 | 0.00% | 1.3752 | 1.4752 | 1.3752 |
| Apr 17, 2025 | 1.4752 | 0.0300 | 2.08% | 1.4452 | 1.4852 | 1.4252 |
| Apr 16, 2025 | 1.4352 | 0.0300 | 2.13% | 1.4052 | 1.4652 | 1.3652 |
| Apr 15, 2025 | 1.3652 | 0.1300 | 10.52% | 1.2352 | 1.4052 | 1.2352 |
| Apr 14, 2025 | 1.2652 | 0.0200 | 1.61% | 1.2452 | 1.3052 | 1.2252 |
| Apr 11, 2025 | 1.2452 | 0.0500 | 4.18% | 1.1952 | 1.2452 | 1.1852 |
| Apr 10, 2025 | 1.1852 | -0.0500 | -4.05% | 1.2352 | 1.2352 | 1.1252 |
| Apr 9, 2025 | 1.2752 | 0.1200 | 10.39% | 1.1552 | 1.3252 | 1.1152 |
| Apr 8, 2025 | 1.1452 | -0.1200 | -9.48% | 1.2652 | 1.3052 | 1.1352 |
| Apr 7, 2025 | 1.2352 | 0.0100 | 0.82% | 1.2252 | 1.3152 | 1.1852 |
| Apr 4, 2025 | 1.3052 | -0.0500 | -3.69% | 1.3552 | 1.3552 | 1.2652 |
| Apr 3, 2025 | 1.3852 | 0.0100 | 0.73% | 1.3752 | 1.4152 | 1.3452 |
| Apr 2, 2025 | 1.4352 | 0.0600 | 4.36% | 1.3752 | 1.4452 | 1.3552 |
| Apr 1, 2025 | 1.3952 | -0.0400 | -2.79% | 1.4352 | 1.4452 | 1.3752 |
| Mar 31, 2025 | 1.4352 | -0.0600 | -4.01% | 1.4952 | 1.4952 | 1.3952 |
| Mar 28, 2025 | 1.5252 | 0.0200 | 1.33% | 1.5052 | 1.5252 | 1.5052 |
| Mar 27, 2025 | 1.5152 | -0.0100 | -0.66% | 1.5252 | 1.5452 | 1.5152 |
| Mar 26, 2025 | 1.5252 | -0.0100 | -0.65% | 1.5352 | 1.5452 | 1.4752 |
| Mar 25, 2025 | 1.5552 | -0.0700 | -4.31% | 1.6252 | 1.6252 | 1.5452 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Compugen Ltd. Company profile
About Compugen Ltd. (USA)
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Compugen Ltd. (USA) revenues increased from $2M to $6M. Net loss increased 15% to $34.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development increase of 24% to $26.7M (expense), Interest Income decrease of 49% to $894K (income).
Equity composition
Ordinary Shares NIS.01 Par, 12/10 50M auth., 33,915,545 issd. Insiders own 11.33%. IPO: 8/11/00, 5M shares @ $10 by FleetBoston Robertson Stephens. FY'00 financials are reclassified.
| Industry: | Biotechnology & Medical Research (NEC) |
26 הרוקמים
HOLON
5885849
IL
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com